Richard W. Pascoe was named Executive Chairman of KemPharm, Inc. in November of 2021 where he has served as a member of the board of directors since 2015. He was previously Chief Executive Officer of Histogen Inc. from January of 2019 to November of 2021. Mr. Pascoe was the Chief Executive Officer of Apricus Biosciences, Inc. from March 2013 until January 2019. Prior to Apricus, Mr. Pascoe was with Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics, Inc.) where he served as the Chief Executive Officer.
Prior to joining Somaxon in 2008, Mr. Pascoe held a series of senior management roles to include Chief Operating Officer at ARIAD Pharmaceuticals, Inc. (acquired by Takeda Inc.) and Senior Vice President of Neuroscience Division at King Pharmaceuticals, Inc. (acquired by Pfizer Inc.). Prior to King, Mr. Pascoe held commercial roles in the hospital pharmaceutical and medical device groups at Medco Research, Inc. (acquired by King), COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals Inc.), and B. Braun Interventional.
Mr. Pascoe is a member of the board of directors of Seelos Therapeutics, Inc. He is the past chairman of the board of directors of Biocom, California’s leading advocate for the life sciences industry, and a member of the Johnny Mac Soldiers Fund, a charity for military veterans.
Mr. Pascoe served on active duty as a commissioned officer with the U.S. Army’s 24th Infantry Division with one combat tour in Iraq where he earned several awards and decorations including the Bronze Star Medal. He is a graduate of the United States Military Academy at West Point where he received a B.S. degree in Leadership. Mr. Pascoe was appointed as the Civilian Aide to the Secretary of the Army for Southern California in 2017, where he served as a liaison between the Secretary of the Army and the local community until November 2021.